Biphasic and dosage-dependent regulation of osteoclastogenesis by β-catenin

Molecular and Cellular Biology

Volumn 31, Issue 23, 2011, Pages 4706-4719

  Wei, W ^a   Zeve, Daniel ^b   Suh, Jae Myoung ^b   Wang, Xueqian ^a   Du, Yang ^a   Zerwekh, Joseph E ^a,c   Dechow, Paul C ^d   Graff, Jonathan M ^a,b   Wan, Yihong ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; COLONY STIMULATING FACTOR 1; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C JUN; TRANSCRIPTION FACTOR GATA 2; WNT PROTEIN;

ALBERS SCHOENBERG DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; HETEROZYGOSITY; HUMAN; INHIBITION KINETICS; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM;

ANIMALS; BETA CATENIN; CATHEPSIN K; CELL DIFFERENTIATION; CELLS, CULTURED; COLLAGEN TYPE I; DNA-BINDING PROTEINS; ENZYME ACTIVATION; GATA2 TRANSCRIPTION FACTOR; GENE EXPRESSION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MICE; MICE, TRANSGENIC; OSTEOCLASTS; OSTEOPETROSIS; PEPTIDE FRAGMENTS; PPAR GAMMA; PROTO-ONCOGENES; RANK LIGAND; TIBIA; TRANSCRIPTION FACTORS;

EID: 83255192191     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.05980-11     Document Type: Article

References (55)

1. Ash, P., J. F. Loutit, and K. M. Townsend. 1980. Osteoclasts derived from haematopoietic stem cells. Nature 283:669-670.
2. Bai, S., et al. 2008. NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. J. Biol. Chem. 283:6509-6518.
3. Bennett, C. N., et al. 2005. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc. Natl. Acad. Sci. U. S. A. 102:3324-3329.
4. Bohmann, D., and R. Tjian. 1989. Biochemical analysis of transcriptional activation by Jun: differential activity of c- and v-Jun. Cell 59:709-717.
5. Brault, V., et al. 2001. Inactivation of the beta-catenin gene by Wnt1-Cremediated deletion results in dramatic brain malformation and failure of craniofacial development. Development 128:1253-1264.
6. Chen, B., et al. 2009. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 5:100-107.
7. Clausen, B. E., C. Burkhardt, W. Reith, R. Renkawitz, and I. Forster. 1999. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8:265-277.
8. Constien, R., et al. 2001. Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 30:36-44.
9. Day, T. F., X. Guo, L. Garrett-Beal, and Y. Yang. 2005. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev. Cell 8:739-750.
10. Diarra, D., et al. 2007. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13:156-163.
11. Fulciniti, M., et al. 2009. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114:371-379.
12. Glass, D. A., II, et al. 2005. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 8:751-764.
13. Harada, N., et al. 1999. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J. 18:5931-5942.
14. Haynes, D. R., et al. 2001. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 40:623-630.
15. Hill, T. P., D. Spater, M. M. Taketo, W. Birchmeier, and C. Hartmann. 2005. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev. Cell. 8:727-738.
16. Holmen, S. L., et al. 2005. Essential role of beta-catenin in postnatal bone acquisition. J. Biol. Chem. 280:21162-21168.
17. Hughes, D. E., et al. 1996. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat. Med. 2:1132-1136.
18. Kameda, T., et al. 1997. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med 186:489-495.
19. Kanda, T., K. F. Sullivan, and G. M. Wahl. 1998. Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells. Curr. Biol. 8:377-385.
20. Kang, S., et al. 2007. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 282:14515-14524.
21. Kawano, H., et al. 2003. Suppressive function of androgen receptor in bone resorption. Proc. Natl. Acad. Sci. U. S. A. 100:9416-9421.
22. Kisanuki, Y. Y., et al. 2001. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev. Biol. 230:230-242.
23. Kong, Y. Y., et al. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309.
24. Kousteni, S., et al. 2002. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298:843-846.
25. Lacey, D. L., et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
26. Lazarenko, O. P., et al. 2007. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148:2669-2680.
27. Li, X., et al. 2009. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24:578-588.
28. Logan, C. Y., and R. Nusse. 2004. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 20:781-810.
29. Mundy, G. R. 2002. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2:584-593.
30. Nakamura, T., et al. 2007. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130:811-823.
31. Novack, D. V., and S. L. Teitelbaum. 2008. The osteoclast: friend or foe? Annu. Rev. Pathol. 3:457-484.
32. Ominsky, M. S., et al. 2010. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J. Bone Miner. Res. 25:948-959.
33. Padhi, D., G. Jang, B. Stouch, L. Fang, and E. Posvar. 2011. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26:19-26.
34. Papavassiliou, A. G., M. Treier, and D. Bohmann. 1995. Intramolecular signal transduction in c-Jun. EMBO J. 14:2014-2019.
35. Pittenger, M. F., et al. 1999. Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
36. Poole, K. E., et al. 2005. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 19:1842-1844.
37. Ricote, M., A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass. 1998. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82.
38. Roodman, G. D. 2004. Mechanisms of bone metastasis. N. Engl. J. Med. 350:1655-1664.
39. Sato, N., L. Meijer, L. Skaltsounis, P. Greengard, and A. H. Brivanlou. 2004. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med. 10:55-63.
40. Takada, I., A. P. Kouzmenko, and S. Kato. 2009. Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat. Rev. Rheumatol. 5:442-447.
41. Tang, W., et al. 2008. White fat progenitor cells reside in the adipose vasculature. Science 322:583-586.
42. Tetsu, O., and F. McCormick. 1999. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426.
43. Tian, E., et al. 2003. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349:2483-2494.
44. Tolar, J., S. L. Teitelbaum, and P. J. Orchard. 2004. Osteopetrosis. N. Engl. J. Med. 351:2839-2849.
45. Tontonoz, P., L. Nagy, J. G. Alvarez, V. A. Thomazy, and R. M. Evans. 1998. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241-252.
46. Tsai, F. Y., et al. 1994. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 371:221-226.
47. Tumbar, T., et al. 2004. Defining the epithelial stem cell niche in skin. Science 303:359-363.
48. Wan, Y., L. W. Chong, and R. M. Evans. 2007. PPAR-gamma regulates osteoclastogenesis in mice. Nat. Med. 13:1496-1503.
49. Wei, W., et al. 2010. PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab. 11:503-516.
50. Wei, W., et al. 2011. Osteoclast progenitors reside in the peroxisome proliferator-activated receptor γ-expressing bone marrow cell population. Mol. Cell. Biol. 31:4692-4705.
51. Yamane, T., et al. 2000. Sequential requirements for SCL/tal-1, GATA-2, macrophage colony-stimulating factor, and osteoclast differentiation factor/osteoprotegerin ligand in osteoclast development. Exp. Hematol. 28:833-840.
52. Yasuda, H., et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 95:3597-3602.
53. Yuasa, H., et al. 2005. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J. 24:1976-1987.
54. Zhang, C., et al. 2008. Inhibition of Wnt signaling by the osteoblast-specific transcription factor Osterix. Proc. Natl. Acad. Sci. U. S. A. 105:6936-6941.
55. Zinman, B., et al. 2010. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 95:134-142.